Market Overview

Citigroup Reiterates Buy Rating, $64 PT on Covidien Ltd.

Share:
Related COV
Reads For The Weed-Kend: Marijuana Roadside Testing, Pregnancy And Depression
Out With The Old, In With The New: State Agencies Seem To Prefer Marijuana Over Opioids

In a report published Wednesday, Citigroup reiterated its Buy rating and $64.00 price target on Covidien Ltd. (NYSE: COV).

Citigroup noted, “We rate Covidien Buy. The company has created strong franchises in general surgery, oximetry/monitoring, ventilation, and peripheral/neurovasculat intervention and has augmented these businesses the past five years via acquisitions. The company is now the third-largest pure play in the med tech space in terms of sales and in the top 10 overall. Covidien's higher-growth businesses also carry higher margins which has created more OM expansion than the peer group and we expect this trend to continue. Covidien also has the unique advantage within our coverage universe of having a domicile outside the United States which means there is no geographic restriction on cash usage.”

Covidien Ltd. closed on Monday at $57.74.

Latest Ratings for COV

DateFirmActionFromTo
Nov 2014JefferiesMaintainsBuy
Oct 2014Morgan StanleyDowngradesOverweightEqual-weight
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for COV
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Reiteration Analyst Ratings

 

Related Articles (COV)

View Comments and Join the Discussion!